Literature DB >> 21245400

Population and high-risk group screening for glaucoma: the Los Angeles Latino Eye Study.

Brian A Francis1, Rohit Varma, Cheryl Vigen, Mei-Ying Lai, Jonathan Winarko, Betsy Nguyen, Stanley Azen.   

Abstract

PURPOSE: To evaluate the ability of various screening tests, both individually and in combination, to detect glaucoma in the general Latino population and high-risk subgroups.
METHODS: The Los Angeles Latino Eye Study is a population-based study of eye disease in Latinos 40 years of age and older. Participants (n = 6082) underwent Humphrey visual field testing (HVF), frequency doubling technology (FDT) perimetry, measurement of intraocular pressure (IOP) and central corneal thickness (CCT), and independent assessment of optic nerve vertical cup disc (C/D) ratio. Screening parameters were evaluated for three definitions of glaucoma based on optic disc, visual field, and a combination of both. Analyses were also conducted for high-risk subgroups (family history of glaucoma, diabetes mellitus, and age ≥65 years). Sensitivity, specificity, and receiver operating characteristic curves were calculated for those continuous parameters independently associated with glaucoma. Classification and regression tree (CART) analysis was used to develop a multivariate algorithm for glaucoma screening.
RESULTS: Preset cutoffs for screening parameters yielded a generally poor balance of sensitivity and specificity (sensitivity/specificity for IOP ≥21 mm Hg and C/D ≥0.8 was 0.24/0.97 and 0.60/0.98, respectively). Assessment of high-risk subgroups did not improve the sensitivity/specificity of individual screening parameters. A CART analysis using multiple screening parameters-C/D, HVF, and IOP-substantially improved the balance of sensitivity and specificity (sensitivity/specificity 0.92/0.92).
CONCLUSIONS: No single screening parameter is useful for glaucoma screening. However, a combination of vertical C/D ratio, HVF, and IOP provides the best balance of sensitivity/specificity and is likely to provide the highest yield in glaucoma screening programs.

Entities:  

Mesh:

Year:  2011        PMID: 21245400      PMCID: PMC3175989          DOI: 10.1167/iovs.09-5126

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Sensitivity and specificity of frequency-doubling technology, tendency-oriented perimetry, and Humphrey Swedish interactive threshold algorithm-fast perimetry in a glaucoma practice.

Authors:  Azfar C Wadood; Augusto Azuara-Blanco; Peter Aspinall; Abdel Taguri; Anthony J W King
Journal:  Am J Ophthalmol       Date:  2002-03       Impact factor: 5.258

Review 2.  Classification and regression tree analysis in public health: methodological review and comparison with logistic regression.

Authors:  Stephenie C Lemon; Jason Roy; Melissa A Clark; Peter D Friedmann; William Rakowski
Journal:  Ann Behav Med       Date:  2003-12

Review 3.  Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach.

Authors:  M J Doughty; M L Zaman
Journal:  Surv Ophthalmol       Date:  2000 Mar-Apr       Impact factor: 6.048

4.  Performance of glaucoma mass screening with only a visual field test using frequency-doubling technology perimetry.

Authors:  Masayuki Tatemichi; Tadashi Nakano; Katsutoshi Tanaka; Takeshi Hayashi; Takeshi Nawa; Toshiaki Miyamoto; Hisanori Hiro; Akio Iwasaki; Minoru Sugita
Journal:  Am J Ophthalmol       Date:  2002-10       Impact factor: 5.258

5.  Diagnostic capabilities of frequency-doubling technology, scanning laser polarimetry, and nerve fiber layer photographs to distinguish glaucomatous damage.

Authors:  J A Paczka; D S Friedman; H A Quigley; Y Barron; S Vitale
Journal:  Am J Ophthalmol       Date:  2001-02       Impact factor: 5.258

6.  Screening for glaucoma with frequency-doubling technology and Damato campimetry.

Authors:  N Yamada; P P Chen; R P Mills; M M Leen; M F Lieberman; R L Stamper; D C Stanford
Journal:  Arch Ophthalmol       Date:  1999-11

7.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

8.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

Review 9.  Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis.

Authors:  Graham Mowatt; Jennifer M Burr; Jonathan A Cook; M A Rehman Siddiqui; Craig Ramsay; Cynthia Fraser; Augusto Azuara-Blanco; Jonathan J Deeks
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-09       Impact factor: 4.799

10.  Central corneal thickness as a risk factor for advanced glaucoma damage.

Authors:  Leon W Herndon; Jennifer S Weizer; Sandra S Stinnett
Journal:  Arch Ophthalmol       Date:  2004-01
View more
  14 in total

1.  Metabolic syndrome: a risk factor for high intraocular pressure in the Israeli population.

Authors:  Tamara Wygnanski-Jaffe; Itzhak Bieran; Dorit Tekes-Manova; Yair Morad; Isaac Ashkenazi; Eedy Mezer
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

2.  A genome-wide association study of central corneal thickness in Latinos.

Authors:  Xiaoyi Gao; W James Gauderman; Yutao Liu; Paul Marjoram; Mina Torres; Talin Haritunians; Jane Z Kuo; Yii-Der I Chen; R Rand Allingham; Michael A Hauser; Kent D Taylor; Jerome I Rotter; Rohit Varma
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-01       Impact factor: 4.799

3.  Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia--Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project.

Authors:  Lisa Hark; Michael Waisbourd; Jonathan S Myers; Jeffrey Henderer; John E Crews; Jinan B Saaddine; Jeanne Molineaux; Deiana Johnson; Harjeet Sembhi; Shayla Stratford; Ayman Suleiman; Laura Pizzi; George L Spaeth; L Jay Katz
Journal:  Ophthalmic Epidemiol       Date:  2016-03-07       Impact factor: 1.648

Review 4.  Biomarkers and surrogate endpoints in glaucoma clinical trials.

Authors:  Felipe A Medeiros
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

5.  Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.

Authors:  Mehrdad Malihi; Edney R Moura Filho; David O Hodge; Arthur J Sit
Journal:  Ophthalmology       Date:  2013-10-25       Impact factor: 12.079

6.  Variants in the ASB10 Gene Are Associated with Primary Open Angle Glaucoma.

Authors:  Shazia Micheal; Humaira Ayub; Farrah Islam; Sorath Noorani Siddiqui; Wajid Ali Khan; Farah Akhtar; Raheel Qamar; Muhammad Imran Khan; Anneke I den Hollander
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

7.  Stereoscopic analysis of optic nerve head parameters in primary open angle glaucoma: the glaucoma stereo analysis study.

Authors:  Yu Yokoyama; Masaki Tanito; Koji Nitta; Maki Katai; Yasushi Kitaoka; Kazuko Omodaka; Satoru Tsuda; Toshiaki Nakagawa; Toru Nakazawa
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

8.  Combining measurements from three anatomical areas for glaucoma diagnosis using Fourier-domain optical coherence tomography.

Authors:  Nils A Loewen; Xinbo Zhang; Ou Tan; Brian A Francis; David S Greenfield; Joel S Schuman; Rohit Varma; David Huang
Journal:  Br J Ophthalmol       Date:  2015-03-20       Impact factor: 4.638

Review 9.  Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.

Authors:  Felipe A Medeiros
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

10.  Cerebrospinal fluid pressure decreases with older age.

Authors:  David Fleischman; John P Berdahl; Jana Zaydlarova; Sandra Stinnett; Michael P Fautsch; R Rand Allingham
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.